Stem cell purging: An intriguing dilemma

V. Rizzoli, C. Carlo-Stella

Research output: Contribution to journalArticle

Abstract

Autologous stem cell transplantation (ASCT) is a therapeutic approach that permits the administration of high-dose chemoradiotherapy followed by the infusion of the patient's own hematopoietic cells, previously collected during remission and cryopreserved [1-4]. The long-term outcome of ASCT is mainly affected by relapse of the underlying disease that represents the major cause of failure of ASCT. The contribution of reinfused tumor cells to relapse is suggested by several clinical studies and has been recently demonstrated by autografting genetically marked cells. In this minireview, advantages and limitations of currently available purging techniques will be analyzed. In addition, the potential clinical implications of new technological approaches for purging will be discussed.

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalExperimental Hematology
Volume23
Issue number4
Publication statusPublished - 1995

Fingerprint

Stem Cell Transplantation
Stem Cells
Recurrence
Autologous Transplantation
Chemoradiotherapy
Neoplasms
Therapeutics

Keywords

  • Autologous stem cell transplantation
  • Minimal residual disease
  • Purging

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Stem cell purging : An intriguing dilemma. / Rizzoli, V.; Carlo-Stella, C.

In: Experimental Hematology, Vol. 23, No. 4, 1995, p. 296-302.

Research output: Contribution to journalArticle

Rizzoli, V. ; Carlo-Stella, C. / Stem cell purging : An intriguing dilemma. In: Experimental Hematology. 1995 ; Vol. 23, No. 4. pp. 296-302.
@article{fec509ec656a44d58117676bfd17586a,
title = "Stem cell purging: An intriguing dilemma",
abstract = "Autologous stem cell transplantation (ASCT) is a therapeutic approach that permits the administration of high-dose chemoradiotherapy followed by the infusion of the patient's own hematopoietic cells, previously collected during remission and cryopreserved [1-4]. The long-term outcome of ASCT is mainly affected by relapse of the underlying disease that represents the major cause of failure of ASCT. The contribution of reinfused tumor cells to relapse is suggested by several clinical studies and has been recently demonstrated by autografting genetically marked cells. In this minireview, advantages and limitations of currently available purging techniques will be analyzed. In addition, the potential clinical implications of new technological approaches for purging will be discussed.",
keywords = "Autologous stem cell transplantation, Minimal residual disease, Purging",
author = "V. Rizzoli and C. Carlo-Stella",
year = "1995",
language = "English",
volume = "23",
pages = "296--302",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Stem cell purging

T2 - An intriguing dilemma

AU - Rizzoli, V.

AU - Carlo-Stella, C.

PY - 1995

Y1 - 1995

N2 - Autologous stem cell transplantation (ASCT) is a therapeutic approach that permits the administration of high-dose chemoradiotherapy followed by the infusion of the patient's own hematopoietic cells, previously collected during remission and cryopreserved [1-4]. The long-term outcome of ASCT is mainly affected by relapse of the underlying disease that represents the major cause of failure of ASCT. The contribution of reinfused tumor cells to relapse is suggested by several clinical studies and has been recently demonstrated by autografting genetically marked cells. In this minireview, advantages and limitations of currently available purging techniques will be analyzed. In addition, the potential clinical implications of new technological approaches for purging will be discussed.

AB - Autologous stem cell transplantation (ASCT) is a therapeutic approach that permits the administration of high-dose chemoradiotherapy followed by the infusion of the patient's own hematopoietic cells, previously collected during remission and cryopreserved [1-4]. The long-term outcome of ASCT is mainly affected by relapse of the underlying disease that represents the major cause of failure of ASCT. The contribution of reinfused tumor cells to relapse is suggested by several clinical studies and has been recently demonstrated by autografting genetically marked cells. In this minireview, advantages and limitations of currently available purging techniques will be analyzed. In addition, the potential clinical implications of new technological approaches for purging will be discussed.

KW - Autologous stem cell transplantation

KW - Minimal residual disease

KW - Purging

UR - http://www.scopus.com/inward/record.url?scp=0028934583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028934583&partnerID=8YFLogxK

M3 - Article

C2 - 7895779

AN - SCOPUS:0028934583

VL - 23

SP - 296

EP - 302

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 4

ER -